“But even in the U.S., I think there's some room for that to continue to creep up a little bit, obviously, running out of room.”

In context

“ain, the portfolio they run at slightly above the targeted procedure levels that we have embedded in the contracts. So they have run very well so far, and it's one of the reasons why we and the customer have expanded those so quickly in recent times. Larry Biegelsen: That's helpful. And leasing in the U.S., where do you see that going? I mean, it was almost -- it was over 70 this quarter and last quarter. Have we plateaued? Or does that continue to go higher? Jamie Samath: On a global basis, we expect the proportion of placements that are leased to continue to find. U.S. is pretty high, as you pointed out, Larry, 70% this quarter, 78% last quarter. There will be some larger IDNs that just routinely prefer to purchase just because of how that affects the metrics that are important to them. But even in the U.S., I think there's some room for that to continue to creep up a little bit, obviously, running out of room. We found a number of U.S. customers have really appreciate that as a way to manage through what are totally managed capital budgets. Larry Biegelsen: Thank you. Operator: Next, we have Brandon Vazquez, William Blair. Please go ahead. Brandon Vazquez: Hi, everyone. Thanks for taking the question. Maybe my first one, I wanted to talk a little bit about general surgery, that's obviously been a nice growth path for you here in the U.S. My understanding is it's a little less penetrated international. What do you think needs to happen in the international markets to kind of get on that steep part of the adoption curve for general surgery as well? Are they kind of seeing time lines and catalysts in the U.S? Gary Guthart: Sure. Thank you for the question. On -- one way to think about it is that g”